-
公开(公告)号：US20120184490A1
公开(公告)日：2012-07-19
申请号：US13379436
申请日：2010-06-23
申请人： Samuel S. Murray , Elsa Murray , Jeffrey Wang , Keyvan Behnam
发明人： Samuel S. Murray , Elsa Murray , Jeffrey Wang , Keyvan Behnam
CPC分类号： A61K38/12 , A61K38/08 , A61K38/10 , A61K38/1841 , A61K38/1875 , A61K2300/00
摘要： The use of autogenous bone graft is the current gold standard in the 1.5 million bone-grafting surgeries performed annually in the United States. Although this practice has resulted in high rates of fusion success, it is associated with increased operative time and blood loss, along with a significant degree of donor-site morbidity. Additionally, in certain settings such as revision cases, multilevel constructs, or in patients with medical comorbidities, autogenous bone graft may exist in limited quantity and quality. This significant need for a suitable alternative to autogenous bone graft has stimulated great interest in the exploration of bone graft substitutes and extenders.
摘要翻译： 在美国每年进行的150万次骨移植手术中，使用自体骨移植是目前的黄金标准。 尽管这种做法导致融合率高，但与手术时间和失血量相关，伴随着供体位点发病率的显着程度。 另外，在某些情况下，例如修订案例，多层次结构，或在具有医学合并症的患者中，自体骨移植可能存在数量有限和质量上的问题。 对于自体骨移植物的合适替代物的这种显着需要刺激了对骨移植物替代物和增量剂的探索的极大兴趣。
-
2.发明授权Enhancement of bone morphogenic protein (BMP) retention with BMP binding peptide (BBP) 有权用BMP结合肽（BBP）增强骨形态发生蛋白（BMP）保留公开(公告)号：US09072709B2
公开(公告)日：2015-07-07
申请号：US13379436
申请日：2010-06-23
申请人： Samuel S. Murray , Elsa Murray , Jeffrey Wang , Keyvan Behnam
发明人： Samuel S. Murray , Elsa Murray , Jeffrey Wang , Keyvan Behnam
CPC分类号： A61K38/12 , A61K38/08 , A61K38/10 , A61K38/1841 , A61K38/1875 , A61K2300/00
摘要： The use of autogenous bone graft is the current gold standard in the 1.5 million bone-grafting surgeries performed annually in the United States. Although this practice has resulted in high rates of fusion success, it is associated with increased operative time and blood loss, along with a significant degree of donor-site morbidity. Additionally, in certain settings such as revision cases, multilevel constructs, or in patients with medical comorbidities, autogenous bone graft may exist in limited quantity and quality. This significant need for a suitable alternative to autogenous bone graft has stimulated great interest in the exploration of bone graft substitutes and extenders.
摘要翻译： 在美国每年进行的150万次骨移植手术中，使用自体骨移植是目前的黄金标准。 尽管这种做法导致融合率高，但与手术时间和失血量相关，伴随着供体位点发病率的显着程度。 另外，在某些情况下，例如修订案例，多层次结构，或在具有医学合并症的患者中，自体骨移植可能存在数量有限和质量上的问题。 对于自体骨移植物的合适替代物的这种显着需要刺激了对骨移植物替代物和增量剂的探索的极大兴趣。
-
搜索结果
2 条记录 (耗时 0.008 秒)
